TMS: What we Can Learn from Stanford Neuromodulation Therapy
At Philadelphia Integrative Psychiatry, we are thrilled to introduce Transcranial Magnetic Stimulation (TMS) as a new treatment option for a range of mental health disorders including depression, anxiety, OCD, addiction, ADHD, and more. This state-of-the-art treatment is now available and insurance-covered for many adults battling depression. Our dedication to offering the most advanced and comprehensive care is highlighted by our investigation into the latest TMS developments, particularly Stanford Neuromodulation Therapy (SNT), as discussed in the "Stanford neuromodulation therapy for treatment-resistant depression: a systematic review" published in *Frontiers in Psychiatry*. Although the specific Saint Protocol is not offered at our facility, insights gained from its research have informed our approach, enabling us to provide similar accelerated TMS treatments tailored for depression and other mental health conditions.
Efficacy of SNT in Treatment-Resistant Depression
The systematic review sheds light on the significant impact of SNT on patients with treatment-resistant depression (TRD). The study analyzed randomized controlled trials (RCTs) and observational studies, revealing that SNT, compared to sham treatments, significantly increased the rates of antidepressant response and remission. Specifically, one RCT showed a response rate of 71.4% versus 13.3% and a remission rate of 57.1% versus 0% in the SNT group compared to the sham. Additionally, single-arm prospective studies reported response rates ranging from 83.3% to 90.5% and remission rates from 66.7% to 90.5%, with no severe adverse events reported across the studies.
Safety and Rapid Action
A paramount concern in the treatment of TRD is the safety and speed of therapeutic effects. The review highlights that SNT significantly improved depressive symptoms within just 5 days of treatment, without any severe adverse events. This rapid improvement is crucial for patients with TRD, who often struggle with the debilitating effects of depression on a daily basis.
Comparison with Other Treatments
SNT's effectiveness is particularly notable when compared to other treatments for TRD. The review points out that the remission rates for SNT are higher than those reported for ketamine treatment, electroconvulsive therapy, and standard FDA-approved repetitive transcranial magnetic stimulation protocols. This positions SNT as a highly effective treatment option for TRD, offering hope to those who have not responded to other forms of treatment.
Implications for Practice
The findings from this systematic review allow Dr. Danish and his team at Philadelphia Integrative Psychiatry to harness the powerful benefits of TMS in treating TRD. By incorporating SNT into our treatment repertoire, we can offer our patients a rapid, safe, and highly effective treatment option. This aligns with our holistic and integrative approach to mental health care, ensuring that we treat the whole person and not just the symptoms.
